Internatl. drug schedulinq
FDA announced in the Sept. 6 Federal Register that a public meeting will be held Oct. 10 at 8:30 am at the agency's Parklawn Bldg. for consideration of the World Health Organization's proposals on internatl. manufacturing and distribution restrictions for certain stimulant and/or hailucinogenic drugs. Agency noted that the Commission on Narcotic Drugs has decided to include dimethoxybromoamphetamine and methylenedioxyamphetamine in Schedule I. The World Health Organization has recommended that 17 stimulant and/or hailucinogenic drug substances be controlled.
You may also be interested in...
Cipla sees an incremental revenue opportunity of up to $500m for its US franchise by fiscal 2025 and expects to propel growth with strong execution of its complex generics pipeline. The company is also beginning to “lay the blueprint” in China and Brazil, it said at the J.P. Morgan Healthcare Conference.
Teva CEO Kåre Schultz believes his prediction is coming true for the Truxima biosimilar in-licensed from Celltrion, as he gave the latest update on Teva’s efforts to settle significant legal issues around the US opioid crisis.
The European Commission has reluctantly allowed virtual audits in the context of new MDR and IVDR. The EU notified body association is helping the collective effort to meet its strict requirements.